drug

pegtibatinase

1 story · latest Aug 4, 2026

Status: Investigational
Codes: OT-058, OT-58, TVT-058
Trials: 2 registered trials in coverage

Relationships

Developed by Travere Therapeutics, Inc.

Timeline

Travere reports Q2 2026 results as FSGS launch begins and civorebrutinib deal closes

Aug 4Quarterly updatepegtibatinase sparsentan

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.